Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Cells ; 12(3)2023 02 03.
Article in English | MEDLINE | ID: mdl-36766843

ABSTRACT

Lens epithelial explants are comprised of lens epithelial cells cultured in vitro on their native basement membrane, the lens capsule. Biologists have used lens epithelial explants to study many different cellular processes including lens fiber cell differentiation. In these studies, fiber differentiation is typically measured by cellular elongation and the expression of a few proteins characteristically expressed by lens fiber cells in situ. Chromatin and RNA was collected from lens epithelial explants cultured in either un-supplemented media or media containing 50% bovine vitreous humor for one or five days. Chromatin for ATAC-sequencing and RNA for RNA-sequencing was prepared from explants to assess regions of accessible chromatin and to quantitatively measure gene expression, respectively. Vitreous humor increased chromatin accessibility in promoter regions of genes associated with fiber differentiation and, surprisingly, an immune response, and this was associated with increased transcript levels for these genes. In contrast, vitreous had little effect on the accessibility of the genes highly expressed in the lens epithelium despite dramatic reductions in their mRNA transcripts. An unbiased analysis of differentially accessible regions revealed an enrichment of cis-regulatory motifs for RUNX, SOX and TEAD transcription factors that may drive differential gene expression in response to vitreous.


Subject(s)
Chromatin , Vitreous Body , Animals , Cattle , Cell Differentiation/genetics , RNA , Immunity, Innate
3.
J Am Acad Dermatol ; 38(1): 69-76, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9448208

ABSTRACT

BACKGROUND: Tacrolimus is a potent immunosuppressant used in organ transplant recipients; an ointment formulation is being developed as a therapeutic agent for atopic dermatitis. OBJECTIVE: Our purpose was to define the pharmacokinetics and evaluate tacrolimus 0.3% ointment as therapy for moderate to severe atopic dermatitis. METHODS: Thirty-nine patients, 5 to 75 years of age, received 14 applications over 8 days. Serial blood samples were collected on days 1 and 8, with predose samples collected on days 2 through 7. Overall response and signs/symptoms were rated daily on days 1 through 11. Incidence of adverse events and laboratory profile were determined. RESULTS: Mean area under the curve (0.9 to 42.5 ng x hr/ml) was highly variable and appeared to be related to size of application area. No systemic accumulation of tacrolimus was observed. Comparison to historical intravenous data indicates that absolute bioavailability of topical tacrolimus was less than 0.5%. Ninety-five percent of patients showed at least good improvement. All adverse events were transient. Burning was the most common application site adverse event and vasodilatation ("flushing/warmth") was the most common nonapplication site adverse event. No drug-related changes in laboratory profile were observed. CONCLUSION: The results of this study suggest that tacrolimus 0.3% ointment may be a safe and effective therapy for atopic dermatitis.


Subject(s)
Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Administration, Cutaneous , Adolescent , Adult , Aged , Area Under Curve , Biological Availability , Child , Child, Preschool , Female , Flushing/chemically induced , Follow-Up Studies , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Immunosuppressive Agents/pharmacokinetics , Incidence , Injections, Intravenous , Male , Middle Aged , Ointments , Remission Induction , Sensation Disorders/etiology , Tacrolimus/administration & dosage , Tacrolimus/adverse effects , Tacrolimus/blood , Tacrolimus/pharmacokinetics , Vasodilation/drug effects
4.
Bioorg Med Chem Lett ; 8(15): 1953-8, 1998 Aug 04.
Article in English | MEDLINE | ID: mdl-9873465

ABSTRACT

The 8-position side chain of 2-pyridones is believed to be involved in the binding with bacterial DNA gyrase to form the ternary complex, making them very important for the activity of 2-pyridones. A series of 2-pyridones having fluoro-substituted amines at the 8-position has been synthesized and their antibacterial activities and parmacokinetic properties are reported.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Pyridones/chemical synthesis , Animals , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Biological Availability , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Half-Life , Microbial Sensitivity Tests , Pyridones/pharmacokinetics , Pyridones/pharmacology , Rats , Structure-Activity Relationship
5.
J Med Chem ; 39(16): 3070-88, 1996 Aug 02.
Article in English | MEDLINE | ID: mdl-8759628

ABSTRACT

Two novel series of 2-pyridones were synthesized by transposition of the nitrogen of 4-quinolones to the bridgehead position. This subtle interchange of the nitrogen atom with a carbon atom yielded two novel heterocyclic nuclei, pyrido[1,2-alpha]pyrimidine and quinolizine, which had not previously been evaluated as antibacterial agents and were found to be potent inhibitors of DNA gyrase. Quinolizines with a methyl group at the 9-position such as (S)-45a (ABT-719) demonstrate exceptional broad spectrum antibacterial activity. Most notably, they are active against resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant strains of enterococci, and ciprofloxacin-resistant organisms. In addition, 2-pyridones also possess favorable physiochemical and pharmacokinetic properties. These 2-pyridones were synthesized from the commercially available starting materials by 10-17 linear transformations. The structure of an adduct yielded by this sequence, (S)-45a (ABT-719), was determined by X-ray crystallographic analysis.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Bacteria/drug effects , Enzyme Inhibitors/chemical synthesis , Pyridones/chemical synthesis , Quinolizines/chemical synthesis , Topoisomerase II Inhibitors , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Crystallography, X-Ray , DNA Topoisomerases, Type II/metabolism , DNA, Bacterial/metabolism , Drug Resistance, Microbial , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Magnetic Resonance Spectroscopy , Microbial Sensitivity Tests , Models, Molecular , Molecular Structure , Pyridones/chemistry , Pyridones/pharmacokinetics , Pyridones/pharmacology , Quinolizines/chemistry , Quinolizines/pharmacokinetics , Quinolizines/pharmacology , Rats , Solubility , Structure-Activity Relationship
6.
Invest Ophthalmol Vis Sci ; 36(3): 671-85, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7890497

ABSTRACT

PURPOSE: To derive norms for monocular grating acuity and interocular acuity differences that are appropriate for clinical applications using the acuity card procedure (ACP) and Teller Acuity Cards (TAC). METHODS: Monocular acuities were measured in 460 children in 12 age groups between 1 month and 4 years. Inclusion criteria were term birth, good general health and normal development, normal eyes, and cycloplegic refraction within specific limits. Each child was tested by two ACP testers who were aware of TAC spatial frequency but not grating location during testing. RESULTS: Three monocular tests were completed in the first session in 99% of children. Median time to complete the tests of both eyes ranged from 3.2 to 8.4 minutes. Monocular acuity norms were calculated using 95% and 99% prediction limits. The new norms spanned higher spatial frequencies than the preliminary ACP norms between ages 1 month and 18 months but were similar between 24 and 36 months. The lower normal 2.5% limits were similar to lower limits of other normative studies. The interocular acuity difference was zero or 0.5 octave in 99% of subjects of all ages. Acuities obtained by the same tester on different days and by different testers on the same day were within 0.5 octave in at least 90% of subjects, comparable to previous studies. CONCLUSIONS: This study provides monocular acuity norms that are appropriate for clinical settings in which the ACP and TAC are used and should replace the preliminary ACP norms.


Subject(s)
Vision Tests/instrumentation , Vision, Monocular/physiology , Visual Acuity/physiology , Child, Preschool , Female , Humans , Infant , Male , Reference Values , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL